Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 6/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.49 |
| ▸ | CDK9 | P50750 | 2/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.49 |
| ▸ | CDK1 | P06493 | 5/20 | 0.45 |
| ▸ | KDR | P35968 | 4/20 | 0.45 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.45 |
| ▸ | PLK1 | P53350 | 2/20 | 0.44 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.44 |
| ▸ | PLK2 | Q9NYY3 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4768983 | 0.88 | AURKA (0.53) | AURKACDK2CCNT1CCNA2CDK9 | |
| SCHEMBL4774317 | 0.88 | AURKA (0.53) | AURKACDK2CCNT1CCNA2CDK9 | |
| SCHEMBL4773980 | 0.87 | AURKA (0.52) | AURKACDK2CCNT1CCNA2CDK9 | |
| SCHEMBL4772099 | 0.87 | CA2 (0.52) | AURKACDK2CCNT1CCNA2CDK9 | |
| SCHEMBL4772198 | 0.86 | AURKA (0.46) | AURKACDK2CCNT1CCNA2CDK9 | |
| SCHEMBL4768143 | 0.86 | SYK (0.53) | AURKACDK2CCNT1CCNA2CDK9 | |
| SCHEMBL4766554 | 0.86 | AURKA (0.46) | AURKACDK2CCNT1CCNA2CDK9 | |
| SCHEMBL4766260 | 0.84 | SYK (0.55) | AURKACDK2CCNT1CCNA2CDK9 | |
| SCHEMBL4772264 | 0.84 | AURKA (0.47) | AURKACDK2CCNT1CCNA2CDK9 | |
| SCHEMBL4763519 | 0.84 | AURKA (0.47) | AURKACDK2CCNT1CCNA2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303496-B9 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-19 | — | — | EP | claimed |
| EP-1303496-B1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-12 | — | — | EP | claimed |
| US-6908920-B2 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2005-06-21 | — | — | US | claimed |
| JP-2004502763-A | — | — | 2004-01-29 | — | — | JP | claimed |
| US-20030216406-A1 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | claimed |
| EP-1303496-A1 | PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | claimed |
| WO-2002004429-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | claimed |
| EP-1303496-B9 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1303496-B1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| US-6908920-B2 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2005-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216406-A1 | Pyrimidine derivatives | TYMP, TYMS, CCNT1 | AURKA 502/4885CDK2 24/4885CCNT1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.